Drugs / [177Lu]Lu DOTA-ABM-5G
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06228482 | Jan 2024 → Jan 2027 expected | non-small cell lung carcinoma | University of California, Davis | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [177Lu]Lu DOTA-ABM-5G | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06228482 ↗ |